New drug interaction study launches in healthy volunteers
NCT ID NCT07444424
First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times
Summary
This early-stage study in 32 healthy adults looks at how a new drug called AZD5004 changes the way the body processes two diabetes medications, mitiglinide and pioglitazone. The goal is to understand potential drug interactions, not to treat any disease. Participants take the drugs in a fixed order, and researchers measure drug levels and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD5004
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Fukuoka, 813-0017, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates